LinkedIn Profile

Access NeuroNascent historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:neuronascent 8487705 Aug 14th, 2020 12:00AM Neuronascent, Inc 62 3.00 Open Pharmaceuticals Aug 14th, 2020 01:48PM Aug 14th, 2020 01:48PM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 Health Care Pharmaceuticals & Biotechnology
private:neuronascent 8487705 Aug 13th, 2020 12:00AM Neuronascent, Inc 62 3.00 Open Pharmaceuticals Aug 13th, 2020 03:39PM Aug 13th, 2020 03:39PM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 Health Care Pharmaceuticals & Biotechnology
private:neuronascent 8487705 Aug 12th, 2020 12:00AM Neuronascent, Inc 62 3.00 Open Pharmaceuticals Aug 12th, 2020 12:50PM Aug 12th, 2020 12:50PM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 Health Care Pharmaceuticals & Biotechnology
private:neuronascent 8487705 Aug 11th, 2020 12:00AM Neuronascent, Inc 62 3.00 Open Pharmaceuticals Aug 11th, 2020 06:35PM Aug 11th, 2020 06:35PM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 Health Care Pharmaceuticals & Biotechnology
private:neuronascent 8487705 Aug 9th, 2020 12:00AM Neuronascent, Inc 62 3.00 Open Pharmaceuticals Aug 9th, 2020 06:06PM Aug 9th, 2020 06:06PM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 Health Care Pharmaceuticals & Biotechnology
private:neuronascent 8487705 Aug 8th, 2020 12:00AM Neuronascent, Inc 62 3.00 Open Pharmaceuticals Aug 8th, 2020 05:35PM Aug 8th, 2020 05:35PM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 Health Care Pharmaceuticals & Biotechnology
private:neuronascent 8487705 Aug 7th, 2020 12:00AM Neuronascent, Inc 62 3.00 Open Pharmaceuticals Aug 7th, 2020 02:17PM Aug 7th, 2020 02:17PM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 Health Care Pharmaceuticals & Biotechnology
private:neuronascent 8487705 Aug 6th, 2020 12:00AM Neuronascent, Inc 62 3.00 Open Pharmaceuticals Aug 6th, 2020 04:38PM Aug 6th, 2020 04:38PM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 Health Care Pharmaceuticals & Biotechnology
private:neuronascent 8487705 Aug 5th, 2020 12:00AM Neuronascent, Inc 62 3.00 Open Pharmaceuticals Aug 5th, 2020 02:58PM Aug 5th, 2020 02:58PM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 Health Care Pharmaceuticals & Biotechnology
private:neuronascent 8487705 Aug 4th, 2020 12:00AM Neuronascent, Inc 62 3.00 Open Pharmaceuticals Aug 4th, 2020 03:01PM Aug 4th, 2020 03:01PM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.